Abstract:Objective To evaluate the clinical efficacy of sitagliptin combined with dapagliflozin in the treatment of type 2 diabetes mellitus（T2DM）complicated with non-alcoholic fatty liver disease（NAFLD），and to explore itsmultiple effects on liver function and glycolipid metabolism in patients. Methods From October 2022 to June 2024，106 T2DM patients with NAFLD admitted to Jingzhou Third People’’s Hospital were included as the study subjects. They were grouped complying with a random number table，with 53 patients in each group. The conventional group received oral treatment with dapagliflozin 10 mg per day，while the combination group received oral treatment with with dapagliflozin 10 mg per day plus sitagliptin 100 mg /d per day. Both groups continued treatment for 8 weeks for evaluation，and the changes in blood glucose，liver function，blood lipids，and insulin related indicators before and after treatment were compared between the two groups. Results After treatment，multiple biochemical indicators inboth groups showed a great downward trend（P<0.05）. Moreover，in the combined group，blood glucose control［fasting plasma glucose（FPG）：（6.84±1.82）mmol/L vs（7.76±1.56）mmol/L，t=2.794，P=0.006］and lipid improvement［totalcholesterol（TC）：（4.58±0.73）mmol/L vs（4.94±0.86）mmol/L，t=2.323，P=0.022；low-density lipoprotein cholesterol（LDL-C）：（2.75±0.86）mmol/L vs（3.19±0.97）mmol/L，t=2.471，P=0.015］and insulin resistance［insulin resistance index（HOMA-IR）：In terms of（4.72±1.49）vs（5.45±1.63），t=2.406，P=0.018，both were significantly better than the conventional group，and the difference was statistically significant（P<0.05）. Conclusion The combination therapy of sitagliptin and dapagliflozin has shown good therapeutic effects in T2DM patients with NAFLD. It can effectively improve glucose and lipid metabolism disorders and promote liver function recovery.